Home Contact Sitemap login Checkout
BioAlberta
  • Home
  • About
    • About
    • From The President
    • What We Do
    • Board of Directors
    • The BioAlberta Team
    • Committees
  • Industry Facts
    • Industry Facts
    • Medical Technology & Devices
    • Health Biotechnology & Pharmaceuticals
    • Agricultural Biotechnology
    • Industrial Biotechnology
    • Functional Foods & Natural Health Products
    • Environmental Biotechnology
    • Industry Terms
    • Subscribe to Our Newsletter
  • Events
    • Events
    • Annual Events & Activities
    • Archived Events
      • Archived Events
      • 2019 Events
      • 2018 Events
      • 2017 Events
      • 2016 Events
      • 2015 Events
      • 2014 Events
  • News
    • News
    • Send us your Press Release
    • News Archive
      • News Archive
      • 2019
      • 2018
      • 2017
      • 2016
      • 2015
      • 2014
  • Member Area
    • Member Area
    • Join Now
    • Member Benefits
      • Member Benefits
      • How To Access Member Benefits
    • Current Members and Life Sciences Industry
    • Current Members by Category
    • Profiled Company
      • Profiled Company
      • Previously Profiled Companies
    • Access to Funding
    • Submit a Photo
    • Job Board
      • Job Board
      • Post a Job
    • Hall Of Fame
  • Publications
    • Publications
    • A Blueprint for Success
    • Bioindustrial Directory 2019
    • HEMP Directory 2019
    • FFNHP Directory 2017
    • Bioindustrial Directory 2017
    • Other Resources
      • Other Resources
      • Archive
  • Contact
    • Contact
    • Send us Feedback
Home Print This Page

Entos Pharmaceuticals Announces Research, Development and Collaboration Agreement



Entos Pharmaceuticals Inc., an Edmonton-based healthcare biotechnology company focused on the development of next generation nucleic acid-based therapies using their Fusogenix drug delivery platform, announced it has entered into a research, development and collaboration agreement with a clinical stage biopharmaceutical Partner focused on the development of novel therapeutic compounds targeting autoimmune and inflammatory diseases.


  • The biopharmaceutical development partner will remain anonymous due to competitive reasons.
  • The companies will collaborate on the formulation and screening of candidates using Entos’ Fusogenix non-viral delivery platform for nucleic acid therapies.
  • The biopharmaceutical partner has the option to exclusively license any candidates developed under this R&D agreement.
  • If the option is exercised, Entos could receive up to US$109 million from the license agreement and undisclosed royalties on sales of products resulting from this collaboration.


Read full press release details.

Contact Us
Suite 202
10055 - 106 Street NW
Edmonton, Alberta T5J 2Y2
Canada
Ph:  780.425.3804
Fx:  780.409.9263
admin@BioAlberta.com
Quick Links
Home
About
Industry Facts
News
Events
Member Area
Publications
Contact
Return Policy
Privacy
Terms of Use
Connect
BioAlberta: Twitter linkBioAlberta: linkedin linkBioAlberta: facebook link